The stock of Dyne Therapeutics Inc (NASDAQ: DYN) has increased by 2.05 when compared to last closing price of 25.31.Despite this, the company has seen a gain of 3.40% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-13 that WALTHAM, Mass., March 13, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.
Is It Worth Investing in Dyne Therapeutics Inc (NASDAQ: DYN) Right Now?
Additionally, the 36-month beta value for DYN is 1.00. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for DYN is 50.99M and currently, short sellers hold a 17.70% ratio of that float. The average trading volume of DYN on May 02, 2024 was 1.29M shares.
DYN’s Market Performance
DYN’s stock has seen a 3.40% increase for the week, with a -7.22% drop in the past month and a 20.70% gain in the past quarter. The volatility ratio for the week is 6.12%, and the volatility levels for the past 30 days are at 5.77% for Dyne Therapeutics Inc The simple moving average for the last 20 days is 0.76% for DYN’s stock, with a simple moving average of 64.51% for the last 200 days.
Analysts’ Opinion of DYN
Many brokerage firms have already submitted their reports for DYN stocks, with Morgan Stanley repeating the rating for DYN by listing it as a “Overweight.” The predicted price for DYN in the upcoming period, according to Morgan Stanley is $40 based on the research report published on April 30, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see DYN reach a price target of $36. The rating they have provided for DYN stocks is “Buy” according to the report published on February 20th, 2024.
Raymond James gave a rating of “Strong Buy” to DYN, setting the target price at $27 in the report published on February 27th of the previous year.
DYN Trading at -1.01% from the 50-Day Moving Average
After a stumble in the market that brought DYN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.66% of loss for the given period.
Volatility was left at 5.77%, however, over the last 30 days, the volatility rate increased by 6.12%, as shares sank -10.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.59% upper at present.
During the last 5 trading sessions, DYN rose by +3.40%, which changed the moving average for the period of 200-days by +133.12% in comparison to the 20-day moving average, which settled at $25.49. In addition, Dyne Therapeutics Inc saw 94.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DYN starting from Farwell Wildon, who sale 1,030 shares at the price of $25.58 back on Mar 12 ’24. After this action, Farwell Wildon now owns 150,560 shares of Dyne Therapeutics Inc, valued at $26,347 using the latest closing price.
Brumm Joshua T, the CEO & President of Dyne Therapeutics Inc, sale 66,387 shares at $25.67 during a trade that took place back on Mar 11 ’24, which means that Brumm Joshua T is holding 537,998 shares at $1,704,142 based on the most recent closing price.
Stock Fundamentals for DYN
Current profitability levels for the company are sitting at:
- -63.93 for the present operating margin
- 0.35 for the gross margin
The net margin for Dyne Therapeutics Inc stands at -61.84. The total capital return value is set at -2.12. Equity return is now at value -137.31, with -100.10 for asset returns.
Based on Dyne Therapeutics Inc (DYN), the company’s capital structure generated 0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -6.86.
Currently, EBITDA for the company is -239.7 million with net debt to EBITDA at 0.39. When we switch over and look at the enterprise to sales, we see a ratio of 528.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.53.
Conclusion
In conclusion, Dyne Therapeutics Inc (DYN) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
